Skip to main content
IMS Events Main banner
    22nd International Myeloma Society Annual Meeting
    Oral Abstract

    Abstract Session 2

    Wednesday, September 17, 2025
    11:00 - 11:50 East Coast USA Time
    Location: Room 718

      Co-Chair(s)

    • Manoj Bhasin, PhD

      Director of Genomics, Proteomics, Bioinformatics and Systems Biology at Children’s Healthcare of Atlanta.
      Emory University
      Atlanta, Georgia

    • Jill Corre, PharmD PhD (she/her/hers)

      Medical biologist
      Unité de Génomique du Myélome, University Hospital, IUCT-Oncopole, CRCT, Toulouse, France
      Toulouse, Midi-Pyrenees, France

    Presentations:

    • 11:00 - 11:10 East Coast USA Time
      (OA-29) In Situ Visualisation of BCMA Bispecific Antibody and the Myeloma Immune Microenvironment

      Abstract Presenter: Jeremy Er, Bmed Sci, MBBS, FRACP, FRCPA – Hawkins laboratory, Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia Clinical haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia

    • 11:10 - 11:20 East Coast USA Time
      (OA-31) A Comprehensive Map of Genomic Drivers of Resistance to Anti-BCMA Immunotherapies in Multiple Myeloma

      Abstract Presenter: Francesco Maura, MD – Memorial Sloan Kettering

    • 11:20 - 11:30 East Coast USA Time
      (OA-10) MZB1-Directed HLA-Dependent CAR T Cells for Targeting B-Cell Malignancies

      Abstract Presenter: Elena Maroto Martin, PhD (she/her/hers) – Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School

    • 11:30 - 11:40 East Coast USA Time
      (OA-15) S100A8/A9 Promotes T Cell Exhaustion and Impairs Response to Bispecific Therapy in Multiple Myeloma

      Abstract Presenter: Oliver Van Oekelen, MD, PhD – Icahn School of Medicine at Mount Sinai

    • 11:40 - 11:50 East Coast USA Time
      (OA-11) Baseline and Longitudinal Immune and Inflammatory Correlates of Response to Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma

      Abstract Presenter: Tarek H. Mouhieddine, MD (he/him/his) – Dana-Farber Cancer Institute